Levetiracetam

Levetiracetam is an antiepileptic drug used in dogs when standard therapies such as phenobarbital or potassium bromide are insufficient or not tolerated.

The medication binds to proteins in nerve cells, thereby preventing the uncontrolled electrical activity that leads to seizures. Unlike older antiepileptics, it places significantly less strain on the liver.

How is levetiracetam dosed?

Levetiracetam is administered several times a day because it is rapidly broken down in the dog’s body. The vet practice determines the exact amount and frequency based on weight, seizure frequency and tolerance; adjusting an antiepileptic without consultation is risky.

The vet adjusts the dose according to seizure frequency and tolerance; the range can vary considerably from dog to dog.

How quickly does levetiracetam work for seizures?

The effect sets in after the first dose, but the full seizure-suppressing effect only develops after 3-5 days of regular intake.

In studies, levetiracetam reduced seizure frequency by at least 50% in 60-70% of treated dogs. As an adjunct therapy to phenobarbital, the success rate increased to up to 85%.

What side effects are possible?

Drowsiness occurs in about 20% of dogs, particularly in the first weeks of treatment.

Behavioural changes such as restlessness or irritability are seen in about 15% of treated dogs. These effects are usually temporary.

Gastrointestinal issues (vomiting, loss of appetite) occur in less than 10%. In contrast to phenobarbital, no liver damage has been documented.

Abrupt discontinuation can trigger status epilepticus. The medication must be tapered off gradually over 1-2 weeks.

When is levetiracetam better than other antiepileptics?

Levetiracetam is particularly suitable for dogs with liver disease, as it is excreted unchanged via the kidneys.

In cluster seizures (multiple seizures within 24 hours), it often shows better results than phenobarbital alone. The combination of both medications achieves seizure freedom in 40-50% of patients, compared with 25% with phenobarbital monotherapy.